ArticleCardio-oncology (London, England)2026
Can flaxseed "milk" prevent anthracycline mediated cardiotoxicity in women with breast cancer (CANFLAX-BC)?
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardio-Oncology focuses on the prevention, diagnosis, and management of individuals with cancer who are at risk of developing cardiovascular complications as a result of their anti-cancer treatment. The aim of the “Can flaxseed “milk” prevent chemotherapy mediated cardiotoxicity in women with breast cancer (CANFLAX-BC) study” was to investigate whether consumption of flaxseed (FLX) “milk” can prevent cardiac dysfunction in women with breast cancer treated with anthracyclines.
methodsIn this small pilot double-blinded, single centre, prospective randomized controlled clinical trial, women with breast cancer were randomized to oral consumption of either placebo oat fiber “milk” or FLX “milk” for a total of 4 months while receiving anthracycline-based chemotherapy. Serial echocardiography and cardiac biomarkers were measured at baseline, 4-months, and 6-months follow-up.
resultsBetween 2021 and 2023, a total of 21 women with early-stage breast cancer (mean age 48 ± 10 years, BMI 28 ± 5 kg/m2), treated with an anthracycline based chemotherapy regimen, were enrolled in the CANFLAX-BC study. During the 4-month intake period, a total of 8 women received oat fibre “milk” and 13 women received FLX “milk” while receiving anthracyclines, with a comparable adherence rate of 70% for both groups. At baseline, 4-months, and 6-months follow-up, the LVEF was 68±4%, 69±3%, and 66±4%, respectively, for the oat fibre “milk” group and 67±5%, 68±4%, and 66±5%, respectively, for the FLX “milk” group (p = NS). Although the mean global longitudinal strain (GLS) was comparable between both groups at baseline, the GLS was lower at -13.8 ± 0.3% (4 months) and − 15.1 ± 0.3% (6 months) for the oat fibre “milk” group as compared to a GLS of -18.4 ± 0.3% (4 months) and − 18.5 ± 0.2% (6 months) for the FLX “milk group (p < 0.05).
conclusionIn women receiving an anthracycline based chemotherapy regimen for breast cancer, this small pilot study suggests that FLX “milk” consumption may prevent early cardiotoxicity as reflected by preservation of GLS parameters.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.